Replimune (REPL) and Iovance (IOVA) are in focus ahead of an FDA decision on REPL’s melanoma drug RP1. While REPL has faced weekly losses, IOVA has recently rallied. Analysts project substantial upside of roughly 116% for REPL and 124% for IOVA. Today’s decision will test investor conviction in REPL’s potential versus IOVA’s approved therapy.